{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:53Z","timestamp":1792289513753,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.intimp.2017.08.018","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T19:02:28Z","timestamp":1505934148000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The potent suppressive effect of \u03b2- d -mannuronic acid (M2000) on molecular expression of the TLR\/NF-kB Signaling Pathway in ankylosing spondylitis patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Maryam","family":"Roozbehkia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Fattahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Jafarnezhad-Ansariha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.0105-2896.2009.00852.x","article-title":"Genetics and genomics of ankylosing spondylitis","volume":"233","author":"Thomas","year":"2010","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4228","article-title":"Microbes, the gut and ankylosing spondylitis","volume":"15","author":"Costello","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2006.02.001","article-title":"Concepts and epidemiology of spondyloarthritis","volume":"20","author":"Sieper","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"14","key":"10.1016\/j.intimp.2017.08.018_bb0020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197304052881403","article-title":"High association of an HL-A antigen, W27, with ankylosing spondylitis","volume":"288","author":"Schlosstein","year":"1973","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2017.08.018_bb0025","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0092-8674(90)90512-D","article-title":"Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human \u03b2 2 m: an animal model of HLA-B27-associated human disorders","volume":"63","author":"Hammer","year":"1990","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.intimp.2017.08.018_bb0035","first-page":"1384","article-title":"WHO-ILAR COPCORD study (stage 1, urban study) in Iran","volume":"35","author":"Davatchi","year":"2008","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2017.08.018_bb0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/03009740903544212","article-title":"Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic","volume":"39","author":"Hanova","year":"2010","journal-title":"Scand. J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0050","first-page":"333","article-title":"Prevalence and clinical characteristics of ankylosing spondylitis in Iceland-a nationwide study","volume":"28","author":"Geirsson","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.44.6.359","article-title":"Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Troms\u00f8, northern Norway","volume":"44","author":"Gran","year":"1985","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.08.018_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TACG.S37325","article-title":"The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis","volume":"7","author":"Tsui F","year":"2014","journal-title":"Appl. Clin. Genet."},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10067-013-2439-4","article-title":"Gender differences in Iranian patients with ankylosing spondylitis","volume":"34","author":"Shahlaee","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2017.08.018_bb0070","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.38644","article-title":"HLA\u2013B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to Spondyloarthritis","volume":"66","author":"Jeanty","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"7809","key":"10.1016\/j.intimp.2017.08.018_bb0075","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","article-title":"Ankylosing spondylitis and HL-A 27","volume":"301","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille","year":"2013","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis","volume":"15","author":"Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0090","first-page":"19","article-title":"Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis","volume":"7","author":"Nicknam","year":"2008","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2017.08.018_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001195","article-title":"Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease","volume":"6","author":"Danoy","year":"2010","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1016\/j.intimp.2017.08.018_bb0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Consortium","year":"2010","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0110","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-\u03baB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2017.08.018_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.08.018_bb0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15171\/apb.2015.082","article-title":"Toll-like receptors in the pathogenesis of autoimmune diseases","volume":"5","author":"Hosseini","year":"2015","journal-title":"Adv. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1443.020","article-title":"Toll-like receptor and RIG-1-like receptor signaling","volume":"1143","author":"Kawai","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2017.08.018_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.22","article-title":"Toll-like receptors: the swiss army knife of immunity and vaccine development","volume":"5","author":"Dowling","year":"2016","journal-title":"Clin. Transl. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12016-013-8402-y","article-title":"TLR2 and TLR4 in autoimmune diseases: a comprehensive review","volume":"47","author":"Liu","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0145","doi-asserted-by":"crossref","first-page":"R1412","DOI":"10.1186\/ar1840","article-title":"Between adaptive and innate immunity: TLR4-mediated perforin production by CD28 null T-helper cells in ankylosing spondylitis","volume":"7","author":"Raffeiner","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0150","first-page":"368","article-title":"Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study","volume":"34","author":"Snelgrove","year":"2007","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2017.08.018_bb0155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nrd914","article-title":"Toll-like receptors as potential therapeutic targets for multiple diseases","volume":"1","author":"Zuany-Amorim","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Karlsson","year":"2007","journal-title":"Inflamm. Allergy Drug Targets"},{"issue":"11","key":"10.1016\/j.intimp.2017.08.018_bb0165","article-title":"TAK-242, a toll-like receptor 4 antagonist, protects against aldosterone-induced cardiac and renal injury","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/jcbfm.2014.240","article-title":"TAK-242, an antagonist for toll-like receptor 4, protects against acute cerebral ischemia\/reperfusion injury in mice","volume":"35","author":"Hua","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0175","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.08.018_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","author":"Poddubnyy","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0185","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CNP60295","article-title":"Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor","volume":"60","author":"Reinhold","year":"2003","journal-title":"Clin. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0195","first-page":"392","article-title":"Alternative treatments for rheumatoid arthritis","volume":"4","author":"Gaby","year":"1999","journal-title":"Altern. Med. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/kem348","article-title":"Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E initiative in rheumatology involving a broad panel of experts and practising rheumatologists","volume":"47","author":"Sidiropoulos","year":"2008","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.intimp.2017.08.018_bb0205","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/rheumatology\/kei046","article-title":"Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab","volume":"44","author":"Sieper","year":"2005","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.intimp.2017.08.018_bb0210","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002530051051","article-title":"Bacterial alginates: biosynthesis and applications","volume":"48","author":"Rehm","year":"1997","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"5","key":"10.1016\/j.intimp.2017.08.018_bb0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-3083.2005.01594.x","article-title":"Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug","volume":"61","author":"Mirshafiey","year":"2005","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","article-title":"Production of M2000 (\u03b2-d-mannuronic acid) and its therapeutic effect on experimental nephritis","volume":"24","author":"Mirshafiey","year":"2007","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/08923970701282387","article-title":"Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis","volume":"29","author":"Mirshafiey","year":"2007","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.08.018_bb0235","article-title":"M2000 (\u03b2-D-mannuronic acid) as a novel antagonist for blocking the TLR2 and TLR4 downstream signaling pathway","author":"Aletaha","year":"2016","journal-title":"Scand. J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","article-title":"Preclinical assessment of \u03b2-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug","volume":"37","author":"Fattahi","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.08.018_bb0245","series-title":"Case Reports in Rheumatology","article-title":"Coexistence of ankylosing spondylitis and Neurofibromatosis type 1","volume":"2016","author":"Gundogdu","year":"2016"},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0250","first-page":"322","article-title":"Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis","volume":"29","author":"Stoll","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.08.018_bb0255","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jmb.2013.11.024","article-title":"Toll-like receptors in antiviral innate immunity","volume":"426","author":"Lester","year":"2014","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2249.2007.03396.x","article-title":"Increased expression of toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis","volume":"149","author":"Yang","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2013.10.009","article-title":"Whole-blood gene expression profiling in ankylosing spondylitis identifies novel candidate genes that may contribute to the inflammatory and tissue-destructive disease aspects","volume":"286","author":"Chen","year":"2013","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.08.018_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3899\/jrheum.100469","article-title":"Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5","volume":"38","author":"Assassi","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2017.08.018_bb0275","first-page":"7","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","author":"Kroon","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2017.08.018_bb0280","first-page":"PI53","article-title":"M2000: a revolution in pharmacology","volume":"11","author":"Mirshafiey","year":"2005","journal-title":"Med. Sci. Monit."},{"issue":"10","key":"10.1016\/j.intimp.2017.08.018_bb0285","article-title":"Chemopreventive effect of M2000, a new anti-inflammatory agent","volume":"10","author":"Mirshafiey","year":"2004","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"10.1016\/j.intimp.2017.08.018_bb0290","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1081\/IPH-200067751","article-title":"Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis","volume":"27","author":"Mirshafiey","year":"2005","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"4","key":"10.1016\/j.intimp.2017.08.018_bb0295","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1081\/IPH-200042362","article-title":"M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis","volume":"26","author":"Mirshafiey","year":"2004","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.08.018_bb0300","article-title":"The biology of \u03b2-D-mannuronic acid (M2000) on human dendritic cell based on MicroRNA-155 and MicroRNA-221","author":"Tabrizian","year":"2016","journal-title":"Curr. Drug Discov. Technol."},{"issue":"3","key":"10.1016\/j.intimp.2017.08.018_bb0305","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1570163813666160621120821","article-title":"The safety property of \u03b2-D-Mannuronic acid (M2000) as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells","volume":"13","author":"Fard","year":"2016","journal-title":"Curr. Drug Discov. Technol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691730317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691730317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T03:40:42Z","timestamp":1719459642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691730317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":61,"alternative-id":["S156757691730317X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.08.018","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potent suppressive effect of \u03b2-d-mannuronic acid (M2000) on molecular expression of the TLR\/NF-kB Signaling Pathway in ankylosing spondylitis patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}